Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10‐Year Cohort

BACKGROUND: Heart failure is a highly prevalent cardiovascular complication among patients receiving long‐term hemodialysis, but the benefits of carvedilol, bisoprolol, and metoprolol controlled release/extended release on the outcomes of these patients remain unclear. In this study, we address the...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Chao‐Hsiun, Wang, Chia‐Chen, Chen, Tso‐Hsiao, Hong, Chuang‐Ye, Sue, Yuh‐Mou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859376/
https://www.ncbi.nlm.nih.gov/pubmed/26738790
http://dx.doi.org/10.1161/JAHA.115.002584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859376/
https://www.ncbi.nlm.nih.gov/pubmed/26738790
http://dx.doi.org/10.1161/JAHA.115.002584

Ejemplares similares